Influence of 6q22‐23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51

Abstract

Based on our earlier observation that deletion of chromosomal region 6q22-23 correlated with shorter survival of primary central nervous system lymphoma (PCNSL) patients (Cady et al, 2008) the overall goal of this study was to further refine the biomarker potential of 6q22-23. We now describe the correlation of its deletion with the overall survival (OS) of patients enrolled on three consecutive North Central Cancer Treatment Group (NCCTG) Phase II clinical trials for newly diagnosed PCNSL, 867252 (O’Neill et al, 1999), 937351 (Laack et al, in press), and 967351 (Laack et al, 2006). Formalin-fixed paraffin embedded blocks (FFPE) from patients enrolled in these three trials were retrieved from the Mayo Clinic Tumor Registry and the Biospecimen Repositories of the 30 participating trial sites (Mayo Foundation Institutional Review Board approval 08-001933). Interphase FISH was performed on thin sections of the FFPE tumour samples following our previously described method (Cady et al, 2008). Survival data were analysed for all patients, with OS being calculated from the date of tissue diagnosis to date of death or last contact. Survival curves were estimated using the Kaplan– Meier method and comparisons were made using the log rank test.